Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update

Protara Therapeutics announced Q3 2026 financial results with $143.1 million in cash and investments. The company expects to complete enrollment of its TARA-002 BCG-Unresponsive registrational cohort by year-end 2026 and complete STARBORN-1 trial enrollment in early Q1 2027, with a rolling BLA submission expected in H2 2027. The company also completed enrollment of the THRIVE-3 Phase 2b trial for IV Choline Chloride and acquired TARA-002 manufacturing assets from Novex Innovations for $8.75 million to bring production in-house.